Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor
JoAnne Foody, MD;, Robin S. Turpin, PhD, Beni A. Tidwell, BS, Debra Lawrence, PhD, Kathy L. Schulman, MS
Gout is a metabolic disorder that causes flares of arthritis in the joints and occurs with the onset of inflammation as a result of excess serum uric acid in the blood (ie, hyperuricemia) and the deposition of crystals in tissue.
The Growing Role of Real-World Evidence in Clinical Decision-Making
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO
Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers
Burton S. Brodsky, MD, Gary M. Owens, MD, Dennis J. Scotti, PhD, MBA, Keith A. Needham, BS, Christina L. Cool, MPH
Ovarian cancer is the eighth most common cancer among women, but ranks fifth in cancer-related causes of death, the majority of which are detected in late stages, after the cancer has metastasized.
Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer
Michael S. Broder, MD, MSHS, Tiffany P. Quock, PhD, MS, Eunice Chang, PhD, Sheila R. Reddy, PhD, RPh, Rajni Agarwal-Hashmi, MD, Sally Arai, MD, Kathleen F. Villa, MS
Cancer is costly. As new cancer therapies become available that extend survival, and as the US population ages and continues to grow, the cost of cancer care is estimated to reach almost $158 billion in 2020, according to the National Cancer Institute.
More Data Analysis Is Needed to Improve Outcomes, Lower Costs, and Maximize Appropriate Resource Use
Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer
Katherine M. Prioli, BS, Laura T. Pizzi, PharmD, MPH, Kathryn M. Kash, PhD, Andrew B. Newberg, MD, Anna Marie Morlino, PharmD, Michael Matthews, BS, Daniel A. Monti, MD
The results of several studies have demonstrated that women and men with a cancer diagnosis benefit from interventions to reduce distress and improve quality of life (QOL). However, little is known about the costs and effectiveness of such interventions.
Creative Therapeutic Activities and Support Groups Benefit All Those Involved in Cancer Care
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide
The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data
Annlouise R. Assaf, PhD, Andrew G. Bushmakin, MS, Nina Joyce, PhD, Michael J. Louie, MD, MPH, MSc, Michael Flores, MPH, Margaret Moffatt, MPH
Budget Impact of a Comprehensive Nutrition-Focused Quality Improvement Program for Malnourished Hospitalized Patients
Suela Sulo, PhD, Josh Feldstein, BA, Jamie Partridge, PhD, MBA, Bjoern Schwander, MS, RN, Krishnan Sriram, MD, Wm. Thomas Summerfelt, PhD
Healthcare is becoming more complex across all disciplines, at all levels, and throughout the world. As a result, practicing medicine that emphasizes the value received from an intervention is increasingly essential to the long-term sustainability of the healthcare delivery model.
The Crucial Role of Nutrition Support Services for Hospitalized Patients
Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas
Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
Kelvin Lingjet Tran, DO, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden.
The GLP-1 Receptor Agonists Are Cost-Effective for the Treatment of Type 2 Diabetes
Page 1 of 3
Results 1 - 10 of 30
Results 1 - 10 of 30